Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.11. Which is the better fit depends on your goals.
| ABEO | VWO | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $61.24 |
52-Week Low | $4.17 | $49.54 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VWO (Vanguard FTSE Emerging Markets ETF) trades at $60.07, up 1.74% on the day, with a bullish technical signal from moving averages. The ETF maintains a low 0.06% expense ratio and a 2.4% dividend yield, positioning it as a cost-efficient emerging markets vehicle. Recent news highlights performance comparisons with competing funds and the impact of South Korea's exclusion from its index, which has contributed to underperformance relative to some peers year-to-date.
The outlook for VWO hinges on broad emerging market growth and its low-cost advantage, but faces risks from geopolitical tensions, index methodology excluding South Korea, and potential underperformance versus developed market funds. The ETF offers diversification but may lag during periods of US market strength or when specific excluded markets outperform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
